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Chronic obstructive pulmonary disease (COPD) is a com-
plex and heterogeneous disease and its definition as a
disease characterised by a non completely reversible air-
flow obstruction mainly caused by cigarette smoke does
not fully describe the variability in its clinical presentation.
The main complain of patients with COPD is exer-
tional dyspnea caused by hyperinflation [1]. Therefore,
the basis of treatment is the optimal bronchodilation,
which is also effective in reducing the future risk of
exacerbations [2]. However, despite optimal bronchodila-
tion, some patients may experience episodes of exacer-
bation. In order to manage these more challenging
patients we need to take into account the diversity of
the disease. In recent years, there has been a growing
interest in defining and characterising the different types
of COPD patients, commonly known as “clinical pheno-
types” [3]. These phenotypes include patients that share
clinical features and similar response to available treat-
ments, and may have prognostic implications [4].
Yet in 2012, the Spanish guidelines of COPD
(GesEPOC) identified four different phenotypes with
clinical relevance and therapeutic repercussion: the
non exacerbator phenotype, the exacerbator pheno-
type with emphysema or with chronic bronchitis and
the asthma-COPD overlap syndrome (ACOS) [5]. The
exacerbator phenotype is defined as two or more exac-
erbations during the previous year [6]. The initial
differentiation between exacerbators and non exacerba-
tors is crucial to prevent the inadequate use of anti-
inflammatory drugs in patients without exacerbations.
Among the exacerbators, GesEPOC identifies three
different phenotypes; frequent exacerbators with em-
physema or with chronic bronchitis and ACOS, which
can also present with frequent exacerbations [7].
Exacerbators with emphysema should receive long
acting bronchodilators (LABD) combined with inhaled
corticosteroids (ICS) when LABD are not enough to
control symptoms and exacerbations, and in particular if
they have high concentrations of eosinophils in peripheral
blood [8]. They can also benefit from pulmonary rehabili-
tation and endoscopic volume reduction in carefully se-
lected cases. For patients with frequent exacerbations and
chronic bronchitis, there are other anti-inflammatories in
addition to ICS that can provide benefits, such as roflumi-
last, mucolytics at high doses or long-term macrolides in
very selected cases and under close supervision [5]. ACOS
patients use to have increased airflow reversibility and
eosinophil counts in sputum and peripheral blood [7].
Some studies demonstrated that patients with COPD and
high eosinophil blood counts treated with ICS presented a
significant reduction in exacerbations compared with
patients treated with LABA alone [9]. Therefore, ACOS
patients should be treated with a combination of LABA/
ICS from early stages, irrespective of the number of exac-
erbations in order to improve symptoms and control
eosinophilic inflammation. Frequently, ACOS patients use
to be asthmatics who smoked and developed non-fully
reversible airflow limitation. In fact, a previous diagnosis
of asthma in a patient with COPD can strongly suggest
the diagnosis of ACOS [10]. Furthermore, LABA/ICS will
be the first line treatment in exacerbators that have evi-
dence of increased eosinophilic inflammation. However,
the debate about the magnitude of eosinophilic inflamma-
tion necessary to consider the use of ICS is still ongoing.
The phenotypic approach to treatment has been
followed by other European guidelines such as the Czech
Republic, the Finnish, the Russian or the Swedish ones
[11]. Some of the previously described phenotypes, such
as the exacerbator or the ACOS, are acknowledged by
all, while the Czech guidelines also include the COPD-
bronchiectasis and the pulmonary cachexia [12].
The identification of clinical phenotypes of COPD
reflects the heterogeneity of the disease and helps
clinicians to select the most suitable treatment for their
patients. The phenotypes proposed in recent guidelines
are easy to identify in routine clinical practice.
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